Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
11.87
-2.90 (-19.63%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Emergent Biosolutions
< Previous
1
2
3
4
5
6
7
8
9
Next >
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
May 04, 2021
Shareholders beware: The hits just won't stop coming.
Via
The Motley Fool
Exposures
COVID-19
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at...
Via
Talk Markets
Exposures
COVID-19
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19...
Via
Benzinga
Exposures
COVID-19
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript
April 30, 2021
EBS earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Emergent BioSolutions: Q1 Earnings Insights
April 29, 2021
Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
A Preview Of Emergent BioSolutions's Earnings
April 28, 2021
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...
Via
Benzinga
Is There Any Hope Left for Emergent BioSolutions?
April 27, 2021
The go-to government contractor is in deep trouble. Should investors buy the dip?
Via
The Motley Fool
Exposures
COVID-19
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ
April 23, 2021
The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Thursday's Intraday Session
April 22, 2021
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Emergent BioSolutions Stock Is Falling Again Today
April 22, 2021
An analyst lowered his price target on the stock.
Via
The Motley Fool
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Thursday
April 22, 2021
On Thursday morning, 5 companies achieved new lows for the year. Interesting Points: Emergent BioSolutions (NYSE:EBS) was the largest, in terms of market cap, to...
Via
Benzinga
FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training
April 21, 2021
The FDA concluded its inspection of Emergent BioSolutions Inc’s (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...
Via
Benzinga
House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify
April 21, 2021
A congressional panel has launched an investigation into whether Emergent BioSolutions Inc (NYSE: EBS) was improperly awarded a $628 million federal...
Via
Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
April 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,...
Via
Benzinga
EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning
April 20, 2021
The European Medicines Agency’s (EMA) safety committee said that the Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine has possible links to...
Via
Benzinga
Exposures
COVID-19
Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility
April 19, 2021
Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson’s (NYSE:...
Via
Benzinga
Exposures
Product Safety
Why Emergent BioSolutions Stock Is Tumbling Today
April 19, 2021
The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward.
Via
The Motley Fool
Exposures
COVID-19
Product Safety
Why Emergent BioSolutions Stock Fell Today
April 13, 2021
The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.
Via
The Motley Fool
Exposures
COVID-19
Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded
April 09, 2021
AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now,...
Via
Benzinga
Exposures
COVID-19
Trouble Is Brewing For J&J's Covid Vaccine — What You Need To Know
April 09, 2021
European regulators are investigating four cases of blood clots in recipients of J&J's coronavirus vaccine. In response, JNJ stock dipped Friday.
Via
Investor's Business Daily
Exposures
COVID-19
US Allocates Significantly Lower Number Of J&J Vaccines To States For Next Week: Reuters
April 08, 2021
The U.S. government will allot around 85% less Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines to states next week, data from the Centers for Disease...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Stock Plagued As Issues Continue To Mount For Covid Vaccine
April 07, 2021
AstraZeneca stock dipped Wednesday after European regulators found a possible link between the company's Covid vaccine and rare cases of blood clots.
Via
Investor's Business Daily
31 Stocks Moving in Thursday's Pre-Market Session
April 01, 2021
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, announced an exclusive partnership to expand...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
April 07, 2021
Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1....
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.